Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ChronoScale Holdings CorpEKSO · Entity 4331 | Chief Financial Officer | May 10, 2018 | June 08, 2018 |
| Globe Photos, Inc.GBPT · Entity 154995 | Chief Financial Officer | August 22, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ChronoScale Holdings Corp
Report date May 10, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,959 |
Ending reported balance
After 2018-05-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-05-10 · Exercise / conversion · Acquired 9,250 · Balance 81,110 F1: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. Row 2 · 2018-05-10 · Tax withholding · Disposed 4,151 · Balance 76,959 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 27,750 |
Reported balance
After 2018-05-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-10 · Exercise / conversion · Disposed 9,250 · Balance 27,750 F1: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. F2: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock.
F2: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
Globe Photos, Inc.
Report date August 22, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,000 |
Reported balance
After 2019-08-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-08-22 · Grant · Acquired 25,000 · Balance 25,000 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: On August 22, 2019, the reporting person was granted 25,000 restricted stock units vesting (i) 50% on the date reporting person began providing services to the issuer and (ii) the remaining 50% on the six-month anniversary of the date reporting person began providing services to the issuer. |
| Employee Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2029-08-21 | Direct | 100,000 |
Reported balance
After 2019-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-08-22 · Grant · Acquired 100,000 · Balance 100,000 F3: On August 22, 2019, the reporting person was granted 100,000 options to purchase common stock which shall vest and become exercisable upon the earlier of (i) the first anniversary of the date reporting person began providing services to the issuer or (ii) the consummation of an underwritten public offering and listing with Nasdaq. |
| Employee Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2029-08-21 | Direct | 125,000 |
Reported balance
After 2019-08-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-08-22 · Grant · Acquired 125,000 · Balance 125,000 F4: On August 22, 2019, the reporting person was granted 125,000 options to purchase common stock which shall vest and become exercisable as follows: 12,500 of the options will vest in the first fiscal quarter in which the Company's trailing twelve month ("TTM") revenues exceed $10,000,000. The remaining options will vest in 12,500 option increments in the first fiscal quarter in which the Company exceeds $10,000,000 in additional TTM revenues. All 125,000 options will vest and become exercisable in the first quarter in which the Company's TTM revenues exceed $30,000,000. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On August 22, 2019, the reporting person was granted 25,000 restricted stock units vesting (i) 50% on the date reporting person began providing services to the issuer and (ii) the remaining 50% on the six-month anniversary of the date reporting person began providing services to the issuer.
F3: On August 22, 2019, the reporting person was granted 100,000 options to purchase common stock which shall vest and become exercisable upon the earlier of (i) the first anniversary of the date reporting person began providing services to the issuer or (ii) the consummation of an underwritten public offering and listing with Nasdaq.
F4: On August 22, 2019, the reporting person was granted 125,000 options to purchase common stock which shall vest and become exercisable as follows: 12,500 of the options will vest in the first fiscal quarter in which the Company's trailing twelve month ("TTM") revenues exceed $10,000,000. The remaining options will vest in 12,500 option increments in the first fiscal quarter in which the Company exceeds $10,000,000 in additional TTM revenues. All 125,000 options will vest and become exercisable in the first quarter in which the Company's TTM revenues exceed $30,000,000.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2019 Filed Aug 23, 2019 09:19 UTC | Globe Photos, Inc. GBPT · Entity 154995 | GrantEmployee Stock Option (Right to buy) · Derivative | 125,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001683168-19-002749 · ownership.xml · derivative · entry 3 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-08-21 F4 · derivative.exercise_date: On August 22, 2019, the reporting person was granted 125,000 options to purchase common stock which shall vest and become exercisable as follows: 12,500 of the options will vest in the first fiscal quarter in which the Company's trailing twelve month ("TTM") revenues exceed $10,000,000. The remaining options will vest in 12,500 option increments in the first fiscal quarter in which the Company exceeds $10,000,000 in additional TTM revenues. All 125,000 options will vest and become exercisable in the first quarter in which the Company's TTM revenues exceed $30,000,000. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 09:19 UTC | Globe Photos, Inc. GBPT · Entity 154995 | GrantEmployee Stock Option (Right to buy) · Derivative | 100,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001683168-19-002749 · ownership.xml · derivative · entry 2 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-08-21 F3 · derivative.exercise_date: On August 22, 2019, the reporting person was granted 100,000 options to purchase common stock which shall vest and become exercisable upon the earlier of (i) the first anniversary of the date reporting person began providing services to the issuer or (ii) the consummation of an underwritten public offering and listing with Nasdaq. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 09:19 UTC | Globe Photos, Inc. GBPT · Entity 154995 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-19-002749 · ownership.xml · derivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 22, 2019, the reporting person was granted 25,000 restricted stock units vesting (i) 50% on the date reporting person began providing services to the issuer and (ii) the remaining 50% on the six-month anniversary of the date reporting person began providing services to the issuer. F2 · derivative.expiration_date: On August 22, 2019, the reporting person was granted 25,000 restricted stock units vesting (i) 50% on the date reporting person began providing services to the issuer and (ii) the remaining 50% on the six-month anniversary of the date reporting person began providing services to the issuer. Read SEC document |
| May 10, 2018 Filed Jun 8, 2018 16:29 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | Exercise / conversionRestricted Stock Units · Derivative | 9,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036693 · doc4.xml · derivative · entry 3 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,750 Underlying: Common Stock · 9,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| May 10, 2018 Filed Jun 8, 2018 16:29 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | Tax withholdingCommon Stock | 4,151 | $1.51 | $6,248.09 |
DisclosureSEC source: 0001209191-18-036693 · doc4.xml · nonDerivative · entry 2 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,959 Read SEC document |
| May 10, 2018 Filed Jun 8, 2018 16:29 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | Exercise / conversionCommon Stock | 9,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-036693 · doc4.xml · nonDerivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:05 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | Tax withholdingCommon Stock | 17,836 | $1.54 | $27,481.71 |
DisclosureSEC source: 0001209191-18-021763 · doc4.xml · nonDerivative · entry 2 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,860 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.56, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 22, 2018 Filed Mar 27, 2018 17:05 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantCommon Stock | 57,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021763 · doc4.xml · nonDerivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,696 Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 13:26 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | PurchaseCommon Stock | 10,000 | $1.13 | $11,300.00 |
DisclosureSEC source: 0001455244-17-000037 · edgar.xml · nonDerivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,371 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.11 to $1.14, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 18:19 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | OtherSubscription Rights (right to buy) · Derivative | 9,817 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001455244-17-000033 · edgar.xml · derivative · entry 2 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,554 shares Expires 2017-08-31 Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 18:19 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | OtherCommon Stock | 12,554 | $1.00 | $12,554.00 |
DisclosureSEC source: 0001455244-17-000033 · edgar.xml · nonDerivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,371 F1 · shares: On August 14, 2017, Ekso Bionics Holdings, Inc. (the "Company") issued a press release announcing the commencement of a pro rata offering (the "Rights Offering") of rights to holders of the Company's common stock and certain holders of warrants issued by the Company, as of the record date of August 10, 2017, to subscribe for up to an aggregate of 34,000,000 shares of common stock. Each subscription right included a basic subscription right, which entitled its holder to purchase 1.1608 shares of common stock at a subscription price of $1.00, and an over-subscription right, which entitled its holder to purchase up to 1.1608 shares of common stock at a subscription price of $1.00, subject to the availability and pro rata allocation of shares among rights holders exercising their over-subscription rights. F2 · shares: The reporting person exercised in full his basic subscription rights, pursuant to which he acquired 11,394 shares of common stock. The reporting person also exercised 1,000 of his over-subscription rights for an additional 1,160 shares of common stock. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 19:19 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantRestricted Stock Units · Derivative | 37,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001578259-17-000012 · edgar.xml · derivative · entry 2 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 19:19 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001578259-17-000012 · edgar.xml · derivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-04-20 F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the total number of shares on the one year anniversary of the date of grant and thereafter vests in equal monthly installments for 36 months. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 14:36 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | PurchaseCommon Stock | 1,000 | $4.00 | $3,995.00 |
DisclosureSEC source: 0001342549-16-000004 · primary_doc.xml · nonDerivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,817 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.986 to $3.996. The Reporting Person undertakes to provide Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.